TABLE 4.
Comparison of Pill Burden and Serum Phosphorus by Residual Urea Clearance (Kru) at Baseline
| Parameter | No Kru Recorded (N=64) | Kru ≤ 3 mL/min/1.73 m2 (N=122) | Kru > 3 mL/min/1.73 m2 (N=72) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| BL | SO | P-value | BL | SO | P-value | BL | SO | P-value | |||
| Phosphate binder pills/day* | 10.7 (0.3) | 4.4 (0.3) | <0.0001 | 10.6 (0.3) | 4.4 (0.3) | <0.0001 | 6.7 (0.3) | 3.7 (0.3) | <0.0001 | ||
| Serum phosphorus (mg/dL) | 6.57 (0.16) | 6.21 (0.15) | 0.001 | 6.96 (0.14) | 6.52 (0.13) | <0.0001 | 5.97 (0.16) | 5.85 (0.15) | 0.22 | ||
| Patients with serum phosphorus ≤ 5.5 mg/dL | 10/64 (15.6%) | 20/64 (31.3%) | 0.008 | 18/122 (14.8%) | 31/122 (25.4%) | 0.012 | 29/72 (40.2%) | 38/72 (52.8%) | 0.049 | ||
BL refers to baseline, SO refers to SO follow-up
Values are expressed as least-squared means (standard error) for continuous variables, and n/N (%) for categorical variables.
P-values compare summary estimates between treatment periods
Abbreviations: Kru= residual urea clearance;